Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact
- 18 April 2023
- journal article
- research article
- Published by Elsevier in Bulletin du Cancer
- Vol. 110 (6) , 605-615
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort studyThe Lancet Oncology, 2013
- Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27Journal of Clinical Oncology, 2012
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trialsThe Lancet, 2011
- Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancerCancer, 2010
- Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Advanced Breast Cancer: Results of Ganglion Sentinelle et Chimiothérapie Neoadjuvante, a French Prospective Multicentric StudyJournal of Clinical Oncology, 2009
- Locally Advanced and Inflammatory Breast CancerJournal of Clinical Oncology, 2008
- Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011Journal of Clinical Oncology, 2007
- Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2006